Loading…

Benefits and safety of transdermal glyceryl trinitrate in acute stroke: A systematic review and meta‐analysis of randomized trials

Background Transdermal glyceryl trinitrate (GTN) has potential beneficial properties in acute stroke including intracerebral hemorrhage (ICH) and possible clinical benefits suggested in ultra‐early stroke (≤6 h). Our meta‐analysis updated the evidence on its safety and benefits in acute stroke. Meth...

Full description

Saved in:
Bibliographic Details
Published in:Academic emergency medicine 2022-06, Vol.29 (6), p.772-788
Main Authors: Lim, Beng Leong, Lee, Wei Feng, Ng, Wei Ming, Situ, Wangmin, Loo, Kee Vooi, Man Goh, Carmen Jia, Chan, Wui Ling
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Transdermal glyceryl trinitrate (GTN) has potential beneficial properties in acute stroke including intracerebral hemorrhage (ICH) and possible clinical benefits suggested in ultra‐early stroke (≤6 h). Our meta‐analysis updated the evidence on its safety and benefits in acute stroke. Methods We searched major electronic databases for randomized trials comparing transdermal GTN versus placebo/control in acute stroke. Primary outcomes were mortality, 90‐day modified Rankin Scale (mRS), and blood pressure (BP) effects. Secondary outcomes included early, late, resource utilization, and surrogate outcomes. Safety outcomes were adverse events. Reviewers identified studies, extracted data, and assessed risk of bias (RoB) using a modified Cochrane RoB instrument and quality of evidence (QoE) using GRADE. We also performed a priori subgroup and trial sequential analyses (TSA) on primary outcomes. These subgroup analyses were ICH versus ischemic stroke, minor (NIHSS ≤5) versus major (NIHSS >5) ischemic stroke, ischemic stroke with versus without thrombolysis, prehospital versus non prehospital settings, time from stroke to randomization ≤6 h versus >6 h, and high versus low overall RoB studies. Results Seven eligible primary trials enrolled 5363 patients. GTN reduced BP (mean difference [MD] = –4.74 mm Hg, 95% confidence interval [CI] = –6.03 to –3.45 mm Hg] and diastolic BP (MD = –2.94 mm Hg, 95% CI = –3.74 to −2.13 mm Hg) 24 h posttreatment but did not affect 4‐ to 10‐day mortality (relative risk [RR] = 1.11, 95% CI = 0.82 to 1.49), 90‐day mortality (RR = 0.96, 95% CI = 0.77 to 1.19), and 90‐day mRS >2 (RR = 0.98, 95% CI = 0.93 to 1.03) compared to control/placebo. The QoE was high for primary outcomes with no subgroup effects detected. GTN did not affect secondary outcomes and increased risk of headache and hypotension. TSA generally supported our conclusions regarding primary outcomes. Conclusions Transdermal GTN reduces BP in acute stroke but does not alter clinical outcomes even in ultra‐early stroke (≤6 h).
ISSN:1069-6563
1553-2712
DOI:10.1111/acem.14408